Published in Gut on May 01, 1998
The stomach in health and disease. Gut (2015) 0.95
Role of endoscopy and biopsy in the work up of dyspepsia. Gut (2002) 0.95
Helicobacter pylori related dyspepsia: prevalence and treatment outcomes at University Kebangsaan Malaysia-Primary Care Centre. Asia Pac Fam Med (2009) 0.77
Prevalence of Helicobacter Pylori Infection and Stress, Anxiety or Depression in Functional Dyspepsia and Outcome after Appropriate Intervention. J Clin Diagn Res (2017) 0.75
Rapid urease test in the management of Campylobacter pyloridis-associated gastritis. Am J Gastroenterol (1987) 4.70
Symptoms in gastro-oesophageal reflux disease. Lancet (1990) 4.10
Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology (1995) 3.86
Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology (1995) 3.28
Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. BMJ (1991) 3.02
Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology (1993) 2.99
The Glasgow Dyspepsia Severity Score--a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol (1996) 2.19
Absence of dyspeptic symptoms as a test of Helicobacter pylori eradication. BMJ (1996) 1.98
The predictive value of history in dyspepsia. Scand J Gastroenterol (1990) 1.42
Detection of Helicobacter pylori infection of the gastric mucosa by measurement of gastric aspirate ammonium and urea concentrations. Gut (1991) 1.31
Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther (1995) 1.03
Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol Suppl (1994) 1.01
The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol (1996) 0.98
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med (1998) 4.99
Diffuse axonal injury due to nonmissile head injury in humans: an analysis of 45 cases. Ann Neurol (1982) 3.82
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet (1998) 3.41
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut (2005) 2.62
Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol (2000) 2.37
The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut (1997) 2.35
Modelling theophylline response in individual patients with chronic bronchitis. Br J Clin Pharmacol (1981) 2.20
Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology (2002) 2.01
Antiprostaglandin synthetase activity of nonsteroidal anti-inflammatory drugs and gastrointestinal micro-bleeding: a comparison of flurbiprofen with benoxaprofen. Ann Rheum Dis (1981) 1.97
The modelling of drug response. Clin Sci (Lond) (1980) 1.79
Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology (2000) 1.74
Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol (1991) 1.72
Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer. Lancet (1989) 1.70
The effects of uterine artery embolisation and surgical treatment on ovarian function in women with uterine fibroids. BJOG (2010) 1.59
Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer (1995) 1.58
Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet (1987) 1.53
Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol (1985) 1.46
Effects of nadolol on arrhythmias during laparoscopy performed under general anaesthesia. Br J Anaesth (1988) 1.41
Imaging with pentavalent [99mTc]DMSA in patients with medullary cancer of the thyroid. J Nucl Med (1988) 1.41
99Tcm-MAG3: problems with radiochemical purity testing. Nucl Med Commun (2000) 1.39
Patient guidance after 131I therapy: time for change? Lancet (1992) 1.38
Comment on article by Oksüzoglu et al. Endoscopy (1998) 1.37
National Congenital Rubella Surveillance Programme 1 July 1971-30 June 1984. Br Med J (Clin Res Ed) (1985) 1.31
The effect of captopril on the reflex control heart rate: possible mechanisms. Br J Clin Pharmacol (1985) 1.29
Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm (1990) 1.29
Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol (2000) 1.21
The neuropathology of the vegetative state after head injury. J Clin Pathol (1999) 1.21
How reproducible is bilateral forearm plethysmography? Br J Clin Pharmacol (1998) 1.21
The neuroinflammatory response in humans after traumatic brain injury. Neuropathol Appl Neurobiol (2013) 1.18
OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacol (1982) 1.15
Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1998) 1.14
Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Pharm Res (1995) 1.13
The prediction of individual systolic time interval v heart rate regression equations. Br J Clin Pharmacol (1981) 1.13
The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology (1998) 1.12
Systolic time interval v heart rate regression equations using atropine: reproducibility studies. Br J Clin Pharmacol (1981) 1.12
Comparative pharmacokinetics and pharmacodynamics of cardiac glycosides. Br J Clin Pharmacol (1980) 1.11
Modeling of drug response in individual subjects. J Pharmacokinet Biopharm (1980) 1.11
Tau immunohistochemistry in acute brain injury. Neuropathol Appl Neurobiol (2003) 1.09
Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm (1993) 1.09
Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth (2002) 1.06
Blood pressure in genetically hypertensive rats. Influence of the Y chromosome. Hypertension (1995) 1.05
Neuropathology in vegetative and severely disabled patients after head injury. Neurology (2001) 1.04
Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol (1984) 1.04
A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience (2007) 1.03
Nifedipine: individual responses and concentration-effect relationships. Hypertension (1988) 1.03
Concentration effect modelling with converting enzyme inhibitors in man. Br J Clin Pharmacol (1983) 1.03
Quantitative trait loci in genetically hypertensive rats. Possible sex specificity. Hypertension (1996) 1.01
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? Br J Cancer (1994) 1.00
Uptake and scanning of the salivary glands in man using pertechnetate-99m-Tc. Clin Sci (1967) 1.00
Comparison of helisal rapid blood test and 14C-urea breath test in determining Helicobacter pylori status and predicting ulcer disease in dyspeptic patients. Am J Gastroenterol (1998) 0.99
Measurement of systolic time intervals. Br J Clin Pharmacol (1978) 0.98
Development of a traumatic intracranial hematoma after a "minor" head injury. Neurosurgery (1990) 0.97
Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm (1995) 0.97
Differentiation between gaseous and formed embolic materials in vivo. Application in prosthetic heart valve patients. Stroke (1994) 0.97
Association of APOE e4 and cerebrovascular pathology in traumatic brain injury. J Neurol Neurosurg Psychiatry (2006) 0.95
A tumour spheroid model for antibody-targeted therapy of micrometastases. Br J Cancer (1988) 0.95
Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther (1988) 0.94
A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer Chemother Pharmacol (1996) 0.94
Mechanisms by which the Hawksley random zero sphygmomanometer underestimates blood pressure and produces a non-random distribution of RZ values. J Hum Hypertens (1997) 0.92
Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol (1992) 0.91
Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. J Pharmacokinet Biopharm (1989) 0.91
Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing. Br Med J (Clin Res Ed) (1984) 0.90
Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant (1998) 0.90
Lacrimal scintigraphy. II. Its role in the diagnosis of epiphora. Br J Ophthalmol (1983) 0.90
Caregivers' perceptions following gastrostomy in severely disabled children with feeding problems. Dev Med Child Neurol (1997) 0.89
The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. Br J Clin Pharmacol (1983) 0.89
Quantitation of dose and concentration-effect relationships for fenclofenac in rheumatoid arthritis. Br J Clin Pharmacol (1986) 0.89
A review of systematic reviews on pain interventions in hospitalized infants. Pain Res Manag (2008) 0.89
Neuropathology of the vegetative state after head injury. Neuropsychol Rehabil (2005) 0.89
The pharmacokinetics of mianserin. Br J Clin Pharmacol (1983) 0.88
Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Int J Clin Pharmacol Res (1985) 0.88
Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. J Cardiovasc Pharmacol (1985) 0.88
The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. J Pharmacokinet Biopharm (1987) 0.88
The effect of luminal content and rate of occlusion on the interpretation of colonic manometry. Neurogastroenterol Motil (2012) 0.88
Lacrimal scintigraphy. I. Compartmental analysis of data. Br J Ophthalmol (1983) 0.88
Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite. J Pharmacokinet Biopharm (1983) 0.87
Energy provision, tissue utilization, and weight loss in prolonged starvation. Br Med J (1974) 0.87
Red cell magnesium as a function of cell age. Metabolism (1980) 0.86
Transient hypothyroidism following radioiodine therapy for thyrotoxicosis. Br J Radiol (1983) 0.86
Correction equation for ECG time intervals. Br J Clin Pharmacol (1984) 0.86
Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype. J Neurol Neurosurg Psychiatry (2005) 0.85
Effect of pretreatment with carbimazole on early outcome following radio-iodine (131I) therapy. Eur J Nucl Med (1984) 0.85
Population pharmacokinetics of rectal theophylline in neonates. Ther Drug Monit (1991) 0.85
The radiation dose to the urinary bladder in radio-iodine therapy. Phys Med Biol (1996) 0.84
BP: a microcomputer program for use in a hypertension clinic. Comput Programs Biomed (1982) 0.84
Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit (1990) 0.84
Evaluation of six gentamicin nomograms using a bayesian parameter estimation program. Ther Drug Monit (1990) 0.84
The neuropathology of the vegetative state and severe disability after non-missile head injury. Acta Neurochir Suppl (Wien) (1983) 0.83
Detection of microemboli by transcranial Doppler ultrasound. Tex Heart Inst J (1996) 0.83
Lacrimal scintigraphy. III. Physiological aspects of lacrimal drainage. Br J Ophthalmol (1983) 0.82
Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects. Br J Clin Pharmacol (1985) 0.82
Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology (2000) 0.82
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br J Cancer (1999) 0.82